Atossa logo
Jan 27, 2021
Registration Is Now Open For Tribe Public's Webinar Event "The Important Role of COVID Therapeutics in a Post-Vaccine World" Featuring Atossa Therapeutics' CEO & CFO On February 2, 2021

Jan 25, 2021
Atossa Therapeutics President and CEO Dr. Steven C. Quay to Speak at Precision Medicine World Conference, Spotlighting Anthony S. Fauci, MD, Director NIAID January 25-27, 2021

Jan 06, 2021
Atossa Therapeutics Announces Pricing of $25.2 Million Registered Direct Offering Priced At-The-Market

Dec 17, 2020
Atossa Therapeutics Announces Pricing of $14.0 Million Registered Direct Offering Priced At-The-Market

Dec 08, 2020
Atossa Therapeutics Announces Pricing of $20.0 Million Underwritten Public Offering

Nov 13, 2020
Atossa Therapeutics Announces Third Quarter 2020 Financial Results and Provides Corporate Update

Nov 10, 2020
Atossa Therapeutics Announces Preliminary Results from Phase 1 Clinical Study Showing Safety and Tolerability of AT-301 Nasal Spray Being Developed for COVID-19

Oct 19, 2020
Atossa Therapeutics Completes Enrollment of Phase 1 Clinical Study of AT-301 Nasal Spray Being Developed for the Coronavirus Causing COVID

Oct 07, 2020
Registration Is Now Open For Atossa Therapeutics' Tribe Public Webinar Presentation and Q&A Event On October 13, 2020

Sep 21, 2020
Atossa Therapeutics To Present at the Oppenheimer & Co. Fall Healthcare Life Sciences and MedTech Summit on September 22, 2020

 1   2   3   4   5     6    7   8   9   10   11